Genflow Biosciences Management

Management criteria checks 2/4

We currently do not have sufficient information about the CEO.

Key information

Eric Leire

Chief executive officer

UK£232.0k

Total compensation

CEO salary percentage100.0%
CEO tenure3.8yrs
CEO ownership35.6%
Management average tenureno data
Board average tenure2.6yrs

Recent management updates

Recent updates

CEO Compensation Analysis

How has Eric Leire's remuneration changed compared to Genflow Biosciences's earnings?
DateTotal CompensationSalaryCompany Earnings
Jun 30 2024n/an/a

-UK£2m

Mar 31 2024n/an/a

-UK£2m

Dec 31 2023UK£232kUK£232k

-UK£2m

Sep 30 2023n/an/a

-UK£1m

Jun 30 2023n/an/a

-UK£1m

Mar 31 2023n/an/a

-UK£1m

Dec 31 2022UK£235kUK£235k

-UK£1m

Jun 30 2022n/an/a

-UK£1m

Mar 31 2022n/an/a

-UK£1m

Dec 31 2021UK£148kUK£148k

-UK£1m

Mar 31 2021n/an/a

-UK£651k

Compensation vs Market: Eric's total compensation ($USD290.47K) is below average for companies of similar size in the German market ($USD462.70K).

Compensation vs Earnings: Eric's compensation has been consistent with company performance over the past year.


CEO

Eric Leire (66 yo)

3.8yrs

Tenure

UK£232,008

Compensation

Dr. Eric Patterson Jean Leire, M.D., MBA, was an Independent Director at PHAXIAM Therapeutics S.A. since 2023 until 2024. He serves as Founder and Chief Executive Officer at Genflow Biosciences plc. and se...


Board Members

NamePositionTenureCompensationOwnership
Eric Leire
Founder3.8yrsUK£232.01k35.62%
€ 2.9m
Guy-Charles de la Horie
Independent Non-Executive Director2.6yrsUK£30.00k0.31%
€ 25.2k
Eric Verdin
Member of Scientific Advisory Boardno datano datano data
Tamara Joseph
Independent Non-Executive Chairperson of the Board2.6yrsUK£30.00k0.23%
€ 18.3k
Yassine Bendiabdallah
Independent Non-Executive Director3.6yrsUK£30.71k0.36%
€ 29.1k
Peter King-Lewis
Independent Non-Executive Director3yrsUK£30.71k0.34%
€ 27.1k
Vera Gorbunova
Chairman of Scientific Advisory Board1.7yrsno datano data
Matthew Hirschey
Member of Scientific Advisory Boardno datano datano data
Manlio Vinciguerra
Member of Scientific Advisory Boardno datano datano data
Sven Francque
Member of Scientific Advisory Board1.7yrsno datano data
Mary Rinella
Member of Scientific Advisory Board1.7yrsno datano data

2.6yrs

Average Tenure

65yo

Average Age

Experienced Board: WQ5's board of directors are not considered experienced ( 2.6 years average tenure), which suggests a new board.


Company Analysis and Financial Data Status

DataLast Updated (UTC time)
Company Analysis2025/01/07 23:37
End of Day Share Price 2025/01/07 00:00
Earnings2024/06/30
Annual Earnings2023/12/31

Data Sources

The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.

PackageDataTimeframeExample US Source *
Company Financials10 years
  • Income statement
  • Cash flow statement
  • Balance sheet
Analyst Consensus Estimates+3 years
  • Forecast financials
  • Analyst price targets
Market Prices30 years
  • Stock prices
  • Dividends, Splits and Actions
Ownership10 years
  • Top shareholders
  • Insider trading
Management10 years
  • Leadership team
  • Board of directors
Key Developments10 years
  • Company announcements

* example for US securities, for non-US equivalent regulatory forms and sources are used.

Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.

Analysis Model and Snowflake

Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.

Learn about the world class team who designed and built the Simply Wall St analysis model.

Industry and Sector Metrics

Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on .

Analyst Sources

Genflow Biosciences plc is covered by 0 analysts. 0 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.

AnalystInstitution